Drug Trial Radar · NCT03486561
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
Last checked: Nov 20, 2026Latest source record: Apr 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Apr 1, 2018
Primary completion
Sep 30, 2018
Study completion Oct 31, 2018
Sponsor
- Lead sponsor
- OBS PakistanIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.
Conditions
- Chronic Stable Angina
Interventions
RanolazineDrug
Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Reduction in frequency of Angina with RanolazineTime frame: 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.